The global Renal Biomarkers Market is estimated to be valued at US$ Mn in 2022 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Renal biomarkers are tests that measure the presence and levels of certain substances in the urine or blood, which indicate the functioning and health of the kidneys. These biomarkers play a crucial role in the early diagnosis, prognosis, and monitoring of kidney diseases. The growing prevalence of chronic kidney diseases and the rising demand for early diagnostic tests are driving the market growth for renal biomarkers. The advantages of renal biomarkers include their ability to detect kidney diseases at an early stage, monitor disease progression, evaluate treatment efficacy, and reduce healthcare costs.
Market key trends:
One key trend in the renal biomarkers market is the continued development of novel biomarkers for kidney diseases. Researchers and healthcare companies are actively involved in identifying and validating new biomarkers that can provide more accurate and comprehensive information about kidney health and disease progression. For example, newer biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and N-acetyl-β-D-glucosaminidase (NAG) are being studied for their potential as early indicators of kidney injury and disease. These advancements in biomarker research are expected to enhance the diagnosis and management of kidney diseases, leading to improved patient outcomes and reduced healthcare costs.
The renal biomarkers market can be segmented based on type, application, and end user. By type, the market is divided into functional biomarkers and predictive biomarkers. The functional biomarkers segment dominates the market due to their ability to provide real-time information about renal function and help in diagnosing acute kidney injury. The increasing prevalence of kidney diseases and the growing demand for early diagnosis and effective treatment options are contributing to the dominance of this segment. Within the functional biomarkers segment, the serum creatinine segment holds a significant market share, driven by its wide usage for assessing kidney function.
By application, the market is segmented into acute kidney injury, chronic kidney diseases, and others. The acute kidney injury segment is expected to witness high growth during the forecast period. This can be attributed to the rising incidence of acute kidney injury due to factors such as drug toxicity, sepsis, and trauma, and the increasing awareness about the severity of the condition.
Based on end user, the market is categorized into hospitals, diagnostic laboratories, and research institutes. The hospitals segment dominates the market owing to the high patient inflow and the availability of advanced diagnostic and treatment facilities. Hospitals are also adopting renal biomarker tests as a part of routine screening procedures, further fueling the growth of this segment.
The Global Renal Biomarkers Market Size is projected to experience significant growth, exhibiting a CAGR of 8.2% during the forecast period of 2023-2030. This growth can be attributed to the increasing prevalence of kidney diseases, the growing geriatric population, and the rising demand for early diagnosis and effective treatment options. The market size for 2021 was estimated to be US$ 1,476.2 million.
In terms of regional analysis, North America is anticipated to be the fastest-growing and dominating region in the renal biomarkers market. This can be attributed to the high prevalence of kidney diseases, the presence of advanced healthcare infrastructure, and the favorable reimbursement policies in the region. Furthermore, the Asia Pacific region is expected to witness significant growth due to the increasing healthcare expenditure, rising awareness about renal biomarker tests, and the growing focus on improving healthcare infrastructure in countries like India and China.
The key players operating in the renal biomarkers market include Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bioporto Diagnostics A/S, Astute Medical, Inc., Randox Laboratories, Sphingo Tec GmbH, Siemens Healthineers AG, Eli Lilly and Company, and Novartis AG. These companies are focusing on strategic collaborations, product launches, and technological advancements to strengthen their market position and expand their product portfolios.